Entrada Therapeutics (TRDA.US): The 2024 Q1 financial report achieved revenue of $59.12 million, previous value of USD 25.26 million, expected value of USD 14.98 million; earnings per share was USD 0.68, previous value was -0.21 USD, and expected value was -0.59 USD.
Entrada Therapeutics(TRDA.US)：2024年Q1财报实现营收5912万美元，前值为2526万美元，预期值为1498万美元；每股收益为0.68美元，前值为-0.21美元，预期值为-0.59美元。
Entrada Therapeutics (TRDA.US): The 2024 Q1 financial report achieved revenue of $59.12 million, previous value of USD 25.26 million, expected value of USD 14.98 million; earnings per share was USD 0.68, previous value was -0.21 USD, and expected value wa
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.